A phase II, single center, open label, randomized-control study to evaluate the recombinant human interleukin-1 receptor antagonist in patients with severe traumatic brain injury.
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2015
At a glance
- Drugs Anakinra (Primary)
- Indications Traumatic stress disorders
- Focus Therapeutic Use
- 17 Sep 2015 New trial record